eClinical Technology and Industy News

IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions

Excerpt from the press release:

“SAN FRANCISCO–(BUSINESS WIRE)–IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of a novel coronavirus disease 2019 (COVID-19), is now a global pandemic. Growing information has demonstrated that a dysregulated and/or hyper-immune response causes a “cytokine storm” with massive increases in cytokines and chemokines which leads to infiltration of immune cells in multiple organs driving the significant co-morbidity and mortality in severe COVID-19. CCL5/RANTES is a chemokine that binds to the chemokine receptor CCR5. CCR5 is expressed on immune cells such as T-lymphocytes, macrophages, and NK cells. CCL5/RANTES acts like a magnet for these cells expressing CCR5. Thus CCL5/RANTES is a marker for the early stages of immune dysregulation in COVID-19 and as a possible therapeutic marker to determine when and how long therapy targeting CCR5 or RANTES should be continued. Other Cytokines included in the COVID-19 Cytokine Panel can be used to monitor other COVID-19 therapeutic approaches targeting other cytokines involved in the cytokine storm.”

Click the button below to read the press release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives